B001-C / Shanghai Pharma - LARVOL DELTA

A novel recombinant anti-cluster of differentiation 20 humanized monoclonal antibody (B001) for the treatment of neuromyelitis optica spectrum disorder: a phase 1, multicenter randomized, double-blind trial. (PubMed, Front Immunol) - P1 | "B001 is a recombinant humanized anti-CD20 monoclonal antibody targeting CD20+ B cells, that has demonstrated superior B cell depletion and anti-proliferative and cytotoxic effects compared to rituximab in a pre-clinical study. B001 demonstrated favorable safety and tolerability, with 700 mg selected as the recommended phase 2 dose. https://clinicaltrials.gov/study/NCT05145361, identifier NCT05145361."

Clinical • Journal • P1 data • CNS Disorders • Dyslipidemia • Infectious Disease • Nephrology • Neuromyelitis Optica Spectrum Disorder • Rare Diseases

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) (clinicaltrials.gov) - P2/3 | N=132 | Not yet recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Initiation date: Jun 2024 ➔ Sep 2024

Trial initiation date • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Rare Diseases

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) (clinicaltrials.gov) - P2/3 | N=132 | Recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Rare Diseases